MX2007005897A - Composiciones farmaceuticas que comprenden un derivado de camptotecina. - Google Patents

Composiciones farmaceuticas que comprenden un derivado de camptotecina.

Info

Publication number
MX2007005897A
MX2007005897A MX2007005897A MX2007005897A MX2007005897A MX 2007005897 A MX2007005897 A MX 2007005897A MX 2007005897 A MX2007005897 A MX 2007005897A MX 2007005897 A MX2007005897 A MX 2007005897A MX 2007005897 A MX2007005897 A MX 2007005897A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
camtothecin
derivate
topoisomerase
inhibitor
Prior art date
Application number
MX2007005897A
Other languages
English (en)
Inventor
Isabel Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35691476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007005897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007005897A publication Critical patent/MX2007005897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a composiciones farmaceuticas novedosas, en donde el agente activo es un inhibidor de topoisomerasa I, en particular un derivado de camptotecina, que es util para el tratamiento y prevencion de enfermedades proliferativas, incluyendo cancer.
MX2007005897A 2004-11-19 2005-11-17 Composiciones farmaceuticas que comprenden un derivado de camptotecina. MX2007005897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62975704P 2004-11-19 2004-11-19
PCT/EP2005/012334 WO2006053755A1 (en) 2004-11-19 2005-11-17 Pharmaceutical compositions comprising a camtothecin derivate

Publications (1)

Publication Number Publication Date
MX2007005897A true MX2007005897A (es) 2007-06-19

Family

ID=35691476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005897A MX2007005897A (es) 2004-11-19 2005-11-17 Composiciones farmaceuticas que comprenden un derivado de camptotecina.

Country Status (28)

Country Link
US (1) US8518961B2 (es)
EP (1) EP1814520B1 (es)
JP (1) JP4982378B2 (es)
KR (1) KR101283840B1 (es)
CN (1) CN101056619A (es)
AR (1) AR052033A1 (es)
AU (1) AU2005306018B2 (es)
BR (1) BRPI0518448A2 (es)
CA (1) CA2584343C (es)
DK (1) DK1814520T3 (es)
ES (1) ES2572133T3 (es)
GT (1) GT200500310A (es)
HR (1) HRP20160446T1 (es)
HU (1) HUE027135T2 (es)
IL (1) IL182703A (es)
MA (1) MA29076B1 (es)
MX (1) MX2007005897A (es)
MY (1) MY148647A (es)
NO (1) NO342592B1 (es)
NZ (1) NZ554551A (es)
PE (1) PE20061077A1 (es)
PL (1) PL1814520T3 (es)
RU (3) RU2007122470A (es)
SI (1) SI1814520T1 (es)
TN (1) TNSN07193A1 (es)
TW (1) TWI368521B (es)
WO (1) WO2006053755A1 (es)
ZA (1) ZA200703148B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
WO2007017514A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin
TW200824686A (en) * 2006-10-31 2008-06-16 Wyeth Corp Formulations of phospholipase enzyme inhibitors
US20100070052A1 (en) * 2008-08-19 2010-03-18 Robb Fujioka System and method for providing applications and peripherals to a fixed price component-based computing platform
MX340819B (es) 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
CN103168037A (zh) 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 激酶抑制剂的合成和用途
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP7218438B2 (ja) 2018-12-19 2023-02-06 コーセプト セラピューティクス， インコーポレイテッド レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物
WO2024042523A1 (en) * 2022-08-24 2024-02-29 Lyotropic Delivery Systems Ltd. Oral delivery of active compounds for treating glycogen storage diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
WO1994014415A1 (en) * 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69823663T2 (de) 1997-07-29 2005-05-19 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierbare formulierung enthaltend lipophile verbindungen
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
JP2002513750A (ja) 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
KR20070058028A (ko) 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CA2461556A1 (en) 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US7223770B2 (en) 2003-10-29 2007-05-29 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2537029C (en) * 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
CA2548078C (en) 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
TWI368521B (en) 2012-07-21
AU2005306018A1 (en) 2006-05-26
NO342592B1 (no) 2018-06-18
RU2015131700A (ru) 2017-02-02
JP4982378B2 (ja) 2012-07-25
MY148647A (en) 2013-05-15
US20080125450A1 (en) 2008-05-29
EP1814520A1 (en) 2007-08-08
CA2584343C (en) 2013-09-24
CN101056619A (zh) 2007-10-17
MA29076B1 (fr) 2007-12-03
EP1814520B1 (en) 2016-04-13
NO20072258L (no) 2007-08-10
US8518961B2 (en) 2013-08-27
DK1814520T3 (en) 2016-05-30
PE20061077A1 (es) 2006-11-13
ZA200703148B (en) 2008-09-25
AR052033A1 (es) 2007-02-28
CA2584343A1 (en) 2006-05-26
PL1814520T3 (pl) 2016-08-31
RU2012120388A (ru) 2013-11-27
TNSN07193A1 (en) 2008-11-21
GT200500310A (es) 2006-06-19
NZ554551A (en) 2010-01-29
WO2006053755A1 (en) 2006-05-26
KR20070084357A (ko) 2007-08-24
RU2007122470A (ru) 2008-12-27
JP2008520606A (ja) 2008-06-19
HRP20160446T1 (hr) 2016-05-20
ES2572133T3 (es) 2016-05-30
BRPI0518448A2 (pt) 2008-11-18
KR101283840B1 (ko) 2013-07-15
AU2005306018B2 (en) 2009-12-17
TW200631606A (en) 2006-09-16
RU2620331C2 (ru) 2017-05-24
IL182703A (en) 2015-11-30
HUE027135T2 (en) 2016-08-29
IL182703A0 (en) 2007-09-20
SI1814520T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
FR16C0021I1 (es)
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
TW200626576A (en) Bicyclic amides as kinase inhibitors
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2007140297A3 (en) Aziridinyl-epothilone compounds
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW200628473A (en) Novel heterocycles
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
WO2007017513A3 (en) Formulations for 7-(t-butoxy)iminomethyl camptothecin
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
WO2006074388A3 (en) TRICYCLIC δ-OPIOID MODULATORS
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2005118584A3 (en) Saframycin analogs as therapeutic agents in the treatment of cancer
WO2009148600A8 (en) Deuterated lysine-based compounds
WO2006066183A3 (en) Novel saframycin analogs as therapeutic agents
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
HK1086493A1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
WO2007059356A3 (en) Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration